Literature DB >> 24173682

Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme.

Eun Young Kim1, Raphael Yechieli, Jin Koo Kim, Tom Mikkelsen, Steven N Kalkanis, Jack Rock, Mark Rosenblum, Samuel Ryu.   

Abstract

Glioblastoma multiforme (GBM) invades beyond enhancing boundaries, and tumor cells are believed to exist in edematous peritumoral regions. We hypothesize that the concomitant treatment of both enhancing and FLAIR abnormalities on MRI by fractionated radiosurgery (FRS) would reduce local and regional recurrence. The purpose of this study was to demonstrate patterns of failure after FRS with simultaneous differential doses to two different target volumes of contrast enhancing lesions with/without FLAIR abnormality in recurrent GBM. Fifty-three patients with recurrent GBM were treated with FRS between 2008 and 2012. FRS was offered for the patients who had progressive tumors after the initial surgical resection followed by chemoradiation, and second-line chemotherapy. Radiosurgery Regimen A was 32 Gy (8 Gy × 4 treatments) to the contrast enhancing lesion only. Regimen B was 32 Gy (8 Gy × 4) to the contrast enhancing lesion and 24 Gy (6 Gy × 4) to the FLAIR abnormality delivered concomitantly. The study endpoint was radiographic failure on MRI at 2 months after FRS. Median survival after FRS was 7.5 months, and median progression-free survival after FRS was 4 months. Overall 82.4 % (42/51 lesions) recurred during follow-up. The local and regional failure rate was significantly lower in Regimen B (52 %) than in Regimen A (86.7 %) (p = 0.003). No sign of tumor progression in 10 % of Regimen A versus 28.6 % of Regimen B was shown during followup (p = 0.04). Instead, distant failure rate was higher in Regimen B. In conclusions, FRS was found to be a safe and effective salvage therapy for recurrent GBM. FRS to both contrast enhancing and FLAIR abnormalities appeared to improve local tumor control, and reduce regional tumor progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24173682     DOI: 10.1007/s11060-013-1290-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

Review 1.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

2.  Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.

Authors:  Shannon E Fogh; David W Andrews; Jon Glass; Walter Curran; Charles Glass; Colin Champ; James J Evans; Terry Hyslop; Edward Pequignot; Beverly Downes; Eileen Comber; Mitchell Maltenfort; Adam P Dicker; Maria Werner-Wasik
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

3.  Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms.

Authors:  P J Kelly; C Daumas-Duport; D B Kispert; B A Kall; B W Scheithauer; J J Illig
Journal:  J Neurosurg       Date:  1987-06       Impact factor: 5.115

4.  Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Authors:  Kyle C Cuneo; James J Vredenburgh; John H Sampson; David A Reardon; Annick Desjardins; Katherine B Peters; Henry S Friedman; Christopher G Willett; John P Kirkpatrick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

5.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Authors:  Stephanie E Combs; Christoph Thilmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

6.  The value of reoperation for recurrent glioblastoma.

Authors:  P Dirks; M Bernstein; P J Muller; W S Tucker
Journal:  Can J Surg       Date:  1993-06       Impact factor: 2.089

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas.

Authors:  Doo-Sik Kong; Jung-Il Lee; Kwan Park; Jong Hyun Kim; Do-Hoon Lim; Do-Hyun Nam
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

9.  Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma.

Authors:  Nader Pouratian; R Webster Crowley; Jonathan H Sherman; Jay Jagannathan; Jason P Sheehan
Journal:  J Neurooncol       Date:  2009-03-29       Impact factor: 4.130

10.  Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma.

Authors:  Dirk Vordermark; Oliver Kölbl; Klemens Ruprecht; Giles H Vince; Klaus Bratengeier; Michael Flentje
Journal:  BMC Cancer       Date:  2005-05-30       Impact factor: 4.430

View more
  7 in total

1.  Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.

Authors:  Christoph Straube; Greeshma Elpula; Jens Gempt; Julia Gerhardt; Stefanie Bette; Claus Zimmer; Friederike Schmidt-Graf; Bernhard Meyer; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2017-06-14       Impact factor: 3.621

2.  Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma.

Authors:  Corbin A Helis; Shih-Ni Prim; Christina K Cramer; Roy Strowd; Glenn J Lesser; Jaclyn J White; Stephen B Tatter; Adrian W Laxton; Christopher Whitlow; Hui-Wen Lo; Waldemar Debinski; James D Ververs; Paul J Black; Michael D Chan
Journal:  Neurooncol Pract       Date:  2022-05-02

Review 3.  Through the patient's eyes: an emphasis on patient-centered values in operative decision making in the management of malignant glioma.

Authors:  Adam M Robin; Steven N Kalkanis; Jack Rock; Ian Lee; Mark L Rosenblum
Journal:  J Neurooncol       Date:  2014-06-25       Impact factor: 4.130

4.  Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions.

Authors:  Elizabeth Scribner; Olivier Saut; Paula Province; Asim Bag; Thierry Colin; Hassan M Fathallah-Shaykh
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

Review 5.  Current status and recent advances in reirradiation of glioblastoma.

Authors:  Giuseppe Minniti; Maximilian Niyazi; Filippo Alongi; Piera Navarria; Claus Belka
Journal:  Radiat Oncol       Date:  2021-02-18       Impact factor: 3.481

Review 6.  Stereotactic Radiosurgery for Glioblastoma.

Authors:  Kristin J Redmond; Minesh Mehta
Journal:  Cureus       Date:  2015-12-17

Review 7.  Laser interstitial thermal therapy as an adjunct therapy in brain tumors: A meta-analysis and comparison with stereotactic radiotherapy.

Authors:  Sabrina Araujo de Franca; Wagner Malago Tavares; Angela Salomao Macedo Salinet; Manoel Jacobsen Teixeira; Wellingson Silva Paiva
Journal:  Surg Neurol Int       Date:  2020-10-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.